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combined with the low total bile salt concentration in the 
biles surrounding brown stones, could decrease choles- 
terol solubility and account for the high percentage of 
this sterol in the stones. Second, addition of lecithin 
enhances interaction of calcium with bile salt micelles 
(31, so that hydrolysis of lecithin might enhance Ca' + 
activity in bile, promoting precipitation of calcium- 
sensitive anions like bile salts (2). On the other hand, 
contrary to the discussion in this paper, lecithin de- 
creases solubilization of bilirubin by bile salt micelles 
(101, so that hydrolysis of lecithin might decrease the 
activity of bilirubinate anions, inhibiting their precipi- 
tation. These latter possibilities need to be assessed 
by studies of the relative effects of (lysolecithin + 
palmitate) vs. lecithin on the binding of Ca++ and 
bilirubinates by bile salt micelles. It is of interest that 
the combined hydrolytic products are just as effective as 
lecithin in enhancing the solubilization of cholesterol by 
mixed bile salt micelles (11). 
Finally, the studies were conducted on brown pigment 
stones obtained from the gallbladders of 28 Japanese 
patients, but it was not stated whether ductal stones 
were present concomitantly. It is thus uncertain 
whether the results can be applied to the brown stones 
that are more often found in the bile ducts alone than the 
gallbladder. Moreover, no information was given re- 
garding the presence of ductal obstruction and/or acute 
cholangitislcholecystitis in these patients, factors that 
might have accounted for some of the observed abnor- 
malities in bile composition. 
In summary, more such carefully performed studies 
are needed, but their value in understanding gallstone 
formation will be diminished if ionized Ca+ + activity is 
not measured also. 
J. DONALD OSTROW, M.D. 
Medical Investigator (151) 
Veterans Administration 
Lakeside Medical Center 
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LICHEN PLANUS AND THE LIVER 
Gruppo Italiano Studi Epidemiologici in Dermatologia 
(GISED).  Lichen planus and liver diseases: a multi- 
center case-control study. BMJ 1990;300:227-230. 
ABSTRACT 
Objective -To assess the association of lichen planus 
with liver complaints and with known etiological 
factors of liver diseases. 
Design -A multicentre case-control study. Inter- 
views were conducted by trained medical investigators 
on the basis of a structured questionnaire. At  the 
interview patients and controls were asked for consent 
to blood samples being taken to determine transami- 
nase activities and the presence of hepatitis B virus 
surface antigen. 
Setting- Outpatient departments of 27 Italian 
general and teaching hospitals that were collaborating 
in the Gruppo Italiano Studi Epidemiologici in Derma- 
tologia (GISED). 
Subjects -Incident cases and controls were eligible. 
A total of 577 patients with lichen planus and 1031 
controls with dermatological diseases other than 
lichen planus were interviewed. Less than 1% of the 
people contacted refused to participate. Patients and 
controls were matched for sex and age in 5 year 
intervals. 
Results-The risk of lichen planus was higher in 
patients with a history of liver diseases requiring 
hospital admission or specialist consultation (relative 
risk = 1.6; 95% confidence interval = 1.2 to 2.2), those 
who had had liver biopsy (5.5; 1.9 to 15.6) and those 
with a history of viral hepatitis (1.9; 1.1 to 3.1). High 
activities of liver enzymes and positive results of tests 
for hepatitis B virus surface antigen were also asso- 
ciated with lichen planus. The association with alcohol 
consumption was not clearly confirmed by a dose-risk 
relationship. 
Conclusion -This study adds quantitative epidemio- 
logical evidence to the clinical obsel-vation that liver 
disease is a risk factor for lichen planus although not a 
specific marker of it. 
COMMENTS 
Lichen planus (LP) is one of the skin conditions that 
delight dermatologists. Since its classical description by 
Willan in 1869, the spectrum of this flat-topped, shiny, 
violaceous eruption of polygonal papules, symmetrically 
distributed and surmounted by fine white linear stria- 
tions, has been expanded with a splendid m a y  of 
elaborately descriptive terminology by many authors. 
The sun-induced LP actinicus, and the blistering from 
LPpemphigoides are aptly named, as are LP annularis 
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and LPatrophicus. LP follicularis involves primarily the 
hair follicles, whereas LP hypertrophicus is a thickened 
variant that occurs primarily on the lower legs. Other 
forms include LP planopilaris, LP tropicus, LP sub- 
tropicus, guttate LP, LP pigmentosus, LP linearis and 
LP erythrodermicus. Some astute observers have even 
reported “invisible LP”. To further color this eruption, 
distinguished names such as Max Joseph, Wickham, 
Koebner, Nekam and Brocq have been associated with 
various clinical or histological features of the disease. 
Because of the broad spectrum of this disease, clinical 
diagnosis, at times, can be difficult. Fortunately, the 
histological findings in developed lesions of LP are dis- 
tinctive, showing a dense, bandlike infiltrate of predom- 
inantly T lymphocytes at the dermoepidermal junction 
and epidermal changes, including degeneration of basal 
cells, hyperkeratosis, and irregular hypergranulosis. 
The cause of LP remains unknown. There appears to 
be a genetic predisposition in some patients as evidenced 
by reports of familial cases and the occurrence of human 
leukocyte antigen DRI in 80% of LP patients compared 
with 25% of control subjects (1). 
Cutaneous eruptions similar to LP can occur with 
exposure to gold, certain drugs (mepacrine, para-amino 
salicylic acid and streptomycin, for example) and, 
strangely, after contact with developers used in pro- 
cessing color photographs. More recently, the de- 
scription of LP eruptions in the chronic phase of 
graft-versus-host disease has restimulated interest in a 
possible autoimmune pathogenesis of this disease, 
further supported by the occurrence of LP in patients 
with lupus erythematosus, vitiligo and alopecia areata. 
Despite these indications, the cause of LP for most 
patients remains a mystery. 
Dermatologists have also attempted to link other 
medical disorders with this fascinating eruption, and the 
growing list of associated conditions includes ulcerative 
colitis, thymoma, myasthenia gravis and hypogamma- 
globulinemia. The liver and its diseases are, a t  present, 
under scrutiny. Initially described in patients with PBC 
receiving D-penicillamine therapy (21, LP was subse- 
quently reported in PBC patients unrelated to therapy 
(Graham-Brown RAC, et al. Lancet 1981;2: 1046, Cor- 
respondence) , although this association was recognized 
to occur only rarely (7  of 268 patients with PBC 
developed LP unrelated to therapy) (3). 
Investigators from Italy, however, reported a startling 
13.5% of patients affected by LP who did not have PBC 
but rather CAH (4). This strong association could not be 
confirmed by investigators from Sweden (51, the United 
Kingdom (Monk B. J Am Acad Dermatol 1985;12:122- 
123, Correspondence) or the United States (Powell FC, 
et al. J Am Acad Dermatol 1984;10:840-841, Corres- 
pondence). This paper is an additional study suggesting 
an association between LP and “liver disease.” It comes 
from 27 predominantly northern Italian outpatient 
dermatology departments and involves 56 regional 
coordinators. Although this study is thought provoking, 
it fails to provide solid evidence of an association 
between LP and hepatic disorders. 
A number of questions must be raised about this study 
and its results. Of the 577 LP patients studied, histo- 
logical confirmation of the diagnosis was required only 
in certain subsets, with the crucial diagnosis of cuta- 
neous disease accepted on clinical features alone for 
most patients, a totally unsatisfactory basis for patient 
selection. Information was then obtained from these 
patients and 1,031 control subjects by interviewers with 
“biomedical training” using a structured questionnaire. 
Analysis of the questionnaire results revealed that 
patients with LP had more “liver complaints requiring 
a specialist consultation,” more frequent history of 
acute viral hepatitis and more liver biopsies, although 
information relating to history of liver biopsy was 
missing for 31 of the control subjects. 
Unfortunately, the kinds of “liver complaints” related 
by these patients are not defined. The patients’ criteria 
for the diagnosis of acute viral hepatitis are not listed, 
and the reason why liver biopsies were carried out is 
unclear. In a previous report (61, one of the participants 
in this study described liver biopsy findings in some 
patients with LP. Inclusion of LP patients being inves- 
tigated in a unit interested in this possible association 
would naturally affect these results. Indeed, it would be 
important to know whether previously identified pa- 
tients with LP and liver disease (6; Rebora A, et d. J Am 
Acad Dermatol 1985;12: 123-124, Correspondence) are 
included in this investigation. If so, the data could be 
recalculated excluding such patients. The findings on 
liver biopsy in the 16 LP patients included 5 who had 
fatty infiltration of the liver and only 3 with CAH. The 
conclusion that “a history of having had a liver biopsy 
gave an estimated risk of LP of about 5,” seems 
unjustified on the basis of such scanty data. 
Levels of ALT and AST activities were elevated more 
often in the LP group, but no details of concomitant drug 
therapy, alcohol exposure or other medical conditions in 
the patients with elevated levels are given, so the 
significance of these abnormal findings is impossible to 
evaluate. Twenty-six of the 561 LP patients tested 
(4.6%) were positive for HBsAg, a finding appreciably 
higher than control subjects in this report, but far lower 
than the occurrence of 34% positivity for one or more 
hepatitis B virus markers in the population of Genoa 
cited by one of the coauthors of this study in previously 
published correspondence (Rebora A, Rongeoletti F. 
J Am Acad Dermatol 1985;12:123-124, Reply), and a 
center for recruitment of patients for this study. 
It is noteworthy, in this regard, that in six contrib- 
uting centers, only one control patient was selected for 
each of 123 patients, a factor that could be significant 
because the frequency of HBsAg positivity seems to vary 
significantly with the Italian population. 
What does this study tell us about the association of 
LP and liver disease? Unfortunately, very little. As the 
authors themselves state, “liver disease” was a “poorly 
defined entity,” and a selection of abnormal blood tests 
or the history of having had a liver biopsy is no 
substitute for clearly identified disease criteria. The 
suggestion that LP could be caused by a “stereotypic 
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cell-mediated reaction to either a specific virus or several 
viruses, some of them hepatotropic” is unwarranted on 
the evidence provided. In the authors’ own words, these 
data are “too vague or speculative” to provide any real 
insight into the enigma of the relationship of lichen 
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HOW DOES ENDOSCOPIC SCLEROTHERAPY 
ALTER SPLANCHNIC HEMODYNAMICS? 
Bourbon P, Zarski JP, Kitmacher P, Bourlard P, 
Machecourt J, Denis B, Rachail M. Esophageal varice 
sclerotherapy: influence on portal pressure and azygos 
blood flow. Gastroenterol Clin Biol 1990;14:244-247. 
ABSTRACT 
Endoscopic sclerotherapy is widely employed for 
esophageal variceal hemorrhage. However it has side 
effects and can aggravate portal hypertension by 
suppression of portosystemic shunt. The purpose of the 
present investigation was to study the effect of variceal 
thrombosis on hepatic venous pressure gradient and 
azygos blood flow. Eight alcoholic cirrhotic patients 
with a first variceal hemorrhage were included. Ac- 
cording to Child Pugh’s classification, 4 patients were 
group A, 2 group B and 2 group C. At each session 40 to 
60 ml of 1 p. 100 polidocanol were injected into the 
varices. A hemodynamic study was performed in each 
patient before and about 1 week after variceal obliter- 
ation (mean 3.3 procedures). Mean value of hepatic 
venous pressure gradient was 16.0 f 5.5 mm Hg and 
17.0 f 3.8, respectively, before sclerotherapy and after 
eradication of varices; azygos blood flow 603 * 506 
mumin before and 682 2 522 after; cardiac output was 
6.5 * 0.7 mumin before and 6.5 * 0.8 after. None of 
these differences were significant. These results 
suggest that endoscopic sclerotherapy using polido- 
canol does not change hepatic venous pressure gra- 
dient and azygos blood flow, and does not lower blood 
flow through the gastroesophageal collaterals draining 
into the azygos vein. This is consistent with the 
hypothesis that thrombosis remains localized. 
COMMENTS 
In his first report of endoscopic sclerotherapy (EST) of 
esophageal varices (EV) in 1947, Moersch suggested that 
EST may increase the risk of bleeding from gastric 
varices, and he considered that the presence of gastric 
fundal varices was a contraindication to the use of EST. 
Since then, the potential hazard of EST in aggravating 
the consequences of portal hypertension has been 
debated. The hypothesis is that EST, by occluding EV 
and, perhaps, para-EV, could thereby reduce the col- 
lateral vessels that shunt blood from the gastric veins. 
Another hazard of EST that has been suggested is the 
occurrence of thrombosis in a major vessel of the portal 
venous system, which could increase the portal venous 
pressure. 
Bourbon et al. suggested, in the work under dis- 
cussion, that EST using polidocanol did not significantly 
alter the hepatic venous pressure gradient and azygos 
blood flow in eight patients with alcoholic cirrhosis who 
had recently bled from ruptured EV. This interesting 
study deserves several comments. First, no control 
group existed. As stated by the authors, this was not 
thought possible for ethical reasons. However, it greatly 
limits the conclusions achievable because it has been 
suggested that a progressive decrease in portal pressure 
occurs after a bleeding event (1) and that portal venous 
pressure falls spontaneously in alcoholic cirrhotic pa- 
tients who have not bled from varices, especially in those 
patients who abstained from alcohol (2). Second, the 
number of patients is low, and large intraindividual 
variations were observed (e.g., portal venous pressure 
fell by 59% in one patient. Third, the use of the thermal 
dilution method for prolonged periods to detect chronic 
variations in azygos blood flow has not been established. 
This measurement is technically difficult, and the 
displacement of the catheter between serial measure- 
ments may introduce methodological errors because it is 
not clear that blood flow is measured in precisely the 
same way. Finally, the authors’ results cannot be 
extrapolated to those with other sclerosing agents 
because it has been suggested that EST with ethanol- 
amine decreases azygos blood flow by almost one fourth 
after eradication of EV (3). It has also been suggested 
that ethanolamine is superior to polidocanol for the 
eradication of EV and the prevention of rebleeding (4), 
even though it has also been suggested that the 
recurrence of EV in patients receiving EST with etha- 
nolamine is caused by incomplete obliteration of the 
venous feeders of the varices ( 5 ) .  
In three other studies, EST did not significantly alter 
portal venous pressure (6). On the other hand, several 
reports have noted gastric or ectopic variceal bleeding 
after EST (61, and it has been suggested that EST 
significantly increases the prevalence of large spleno- 
